EW vs ZYME · P/E 47, rev $1.39B vs rev $76.3M
Edwards Lifesciences Corp (EW) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported EW revenue for 2024-12-31 was $1.39B. Net income was $385.6M. Revenue was up 2.3% from 2024-09-30 to 2024-12-31. EW currently screens at market cap $49.91B and trailing P/E 46.9.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
EW currently screens at market cap $49.91B and trailing P/E 46.9. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the EW and ZYME stock pages for the full models.
Not investment advice.